期刊文献+

替米沙坦对同型半胱氨酸诱导内皮细胞炎症损伤及对p38MAPK通路的影响 被引量:1

Effects of Telmisartan on Homocysteine-Induced Endothelial Cell Inflammation and p38MAPK Pathway
下载PDF
导出
摘要 目的:探讨替米沙坦对同型半胱氨酸诱导内皮细胞炎症损伤及对p38MAPK通路的影响。方法:设MS-1内皮细胞组(MS-1内皮细胞)、同型半胱氨酸组(5 mg·L^(-1)同型半胱氨酸+MS-1内皮细胞)、替米沙坦组(5 mg·L^(-1)同型半胱氨酸+50 mg·L^(-1)替米沙坦+MS-1内皮细胞),培养结束后,检测各组细胞活力和凋亡率、G1期水平、白细胞介素-2(IL-2)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)蛋白表达水平、p-p38MAPK mRNA及蛋白水平、半胱氨酸蛋白酶-3(caspase-3)、半胱氨酸蛋白酶-6(caspase-6)、半胱氨酸蛋白酶-9(caspase-9)蛋白表达水平。结果:与MS-1内皮细胞组比较,同型半胱氨酸组和替米沙坦组活力、G1期水平显著降低(P <0. 05);凋亡率、IL-2、IL-6、TNF-α蛋白水平、p-p38MAPK mRNA及蛋白水平、caspase-3、caspase-6、caspase-9蛋白水平显著升高(P <0. 05)。与同型半胱氨酸组比较,替米沙坦组活力、G1期水平显著升高(P <0. 05);凋亡率、IL-2、IL-6、TNF-α蛋白水平、p-p38MAPK mRNA及蛋白水平、caspase-3、caspase-6、caspase-9蛋白水平显著降低(P <0. 05)。结论:替米沙坦对同型半胱氨酸诱导的内皮细胞炎症损伤具有保护作用,其机制与替米沙坦抑制p38MAPK炎症信号通路的激活及抑制内皮细胞凋亡有关。 Objective:To investigate the effects of telmisartan on homocysteine-induced endothelial cell inflammation and p38 MAPK pathway.Methods:The cells were divided into MS^-1 endothelial cell group(MS^-1 endothelial cells),homocysteine group(5 mg·L^-1 homocysteine+MS^-1 endothelial cells)and telmisartan group(5 mg·L^-1 homocysteine+50 mg·L^-1 telmisartan+MS^-1 endothelial cells).After the culture,the viability,apoptosis rate,cells arrested at G1 phase,IL-2,IL-6,TNF-αprotein expression,mRNA and protein expression levels of p-p38 MAPK,as well as the protein expression levels of caspase-3,caspase-6 and caspase-9 were detected.Results:Compared with those in MS^-1 endothelial cell group,the cell viability and G1 level in homocysteine group and telmisartan group were significantly decreased(P<0.05),and the apoptosis rate,protein expression levels of IL-2,IL-6 and TNF-α,mRNA and protein expression levels of p-p38 MAPK,as well as the protein expression levels of caspase-3,caspase-6 and caspase-9 were significantly increased(P<0.05).Compared with those in homocysteine group,the cell viability and G1 level in telmisartan group were significantly increased(P<0.05),and the apoptosis rate,protein expression levels of IL-2,IL-6 and TNF-α,mRNA and protein expression levels of p-p38 MAPK,as well as the protein expression levels of caspase-3,caspase-6 and caspase-9 were significantly decreased(P<0.05).Conclusion:The protective effect of telmisartan on homocysteine-induced endothelial cell inflammatory injury is related to the inhibition of p38 MAPK inflammatory signaling pathway activation and endothelial cell apoptosis.
作者 吴刚 袁华兵 陈腊梅 Wu Gang;Yuan Huabing;Chen Lamei(Department of Pharmacy,Tianmen First People's Hospital,Hubei Tianmen 431700,China)
出处 《中国药师》 CAS 2019年第5期809-813,共5页 China Pharmacist
关键词 替米沙坦 同型半胱氨酸 内皮细胞 炎症损伤 P38MAPK Telmisartan Homocysteine Endothelial cells Inflammatory injury p38MAPK
  • 相关文献

参考文献4

二级参考文献41

  • 1刘力生.2004年中国高血压防治指南(实用本)[J].中华心血管病杂志,2004,32(12):1060-1064. 被引量:2620
  • 2李立明,饶克勤,孔灵芝,姚崇华,向红丁,翟凤英,马冠生,杨晓光,中国居民营养与健康状况调查技术执行组.中国居民2002年营养与健康状况调查[J].中华流行病学杂志,2005,26(7):478-484. 被引量:1783
  • 3常健,鲁继荣,梁东,李海波,陈银波,赵红霞.川崎病患儿急性期Th1/Th2细胞功能状态的研究[J].中华儿科杂志,2006,44(5):377-378. 被引量:8
  • 4中华医学会糖尿病学分会.中国糖尿病防治指南[M].北京:人民卫生出版社,2005:2-28.
  • 5Chen G, McAlister FA, Walker RL, et al. Cardiovascular outcomes in framingham participants with diabetes: the impgrtance of blood pressure [ J 1. Hypertension,2011,57 ( 5 ) : 891-897.
  • 6Genuth S. The UKPDS and its global impact[ J]. Diabet Med,2008,25 ( Suppl 2 ) :57-62.
  • 7Chobanian AV,Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [ J]. Hypertension ,2003,42 ( 6 ) : 1206-1252.
  • 8Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus . Provisional report of a WHO consultation [J]. Diabetic Medicine, 1998,15 ( 7 ) : 539-553.
  • 9Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus [ J ]. Diabetes Care, 1997,20 ( 7 ) : 1183-1197.
  • 10Jadad APt, Moore A, Carrol D, et al. Assessing the quality of reports of randomized clinical trials : is blinding necessary[ J 1. Control Clin Trials, 1996,17(1 ) :1-12.

共引文献213

同被引文献10

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部